IRB #
STUDY00024305
Title
CAMPERR: cfMeDIP-seq Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse
Principal Investigator
Nima Nabavizadeh
Study Purpose
To train and validate Adela’s cfMeDIP-seq based methylome profiling platform to detect and differentiate multiple cancer subtypes.
Medical Condition(s)
Healthy volunteers, Cancer screening, brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid
Eligibility Criteria
1. ≥40 years of age
2. Able and willing to provide informed consent
3. Should meet one of the following conditions at the time of enrollment:
a) Newly diagnosed (within 90 days) with cancer or a recurrence of a cancer diagnosed >5 years ago of one of the following subtypes: Invasive Brain, Breast, Bladder, Cervical, Colorectal, Endometrial, Esophageal, Gastric, Head and Neck, Hepatobiliary, Lung, Ovarian, Pancreatic, Prostate, Renal, Sarcoma, Thyroid, Leukemia, Lymphoma, Multiple Myeloma
b) Not diagnosed with any cancer in the last 5 years (except ductal carcinoma in situ or non-melanoma skin cancer)
Age Range
40 - N/A
Healthy Volunteers Needed
Yes
Duration of Participation
This study is expected to take approximately 5 years. This includes approximately 1 year for enrollment, with up to 3 years of follow-up for the controls and up to 4 years of follow-up for the cancer cases
Minors Included
No
Contact
cedartrials@ohsu.edu
503-418-8150
Sponsor
Adela, Inc.
Recruitment End
04/01/2027
Compensation Provided
Yes
Compensation
$50 per blood draw
Go Back